Finally, guideline-directed therapies in patients with CAD with concurrent heart failure includes renin-angiotensin system blockers, beta blockers, and mineralocorticoid receptor antagonists—each of which have blood pressure–lowering effects. The gene discussed is NR3C2; the disease is coronary artery disorder.